Robert S. Shapard
Known title: DirectorCIK: 0001121300
Robert S. Shapard's purchase track record
Robert S. Shapard has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/4/2023 | LDOS | $393K | +24.4% | +30.9% | +6.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| NC | ▲ Buy | Grant | 663 | — | 10/1/2026 | View on chart |
| LDOS | ▲ Buy | Grant | 6 | $0 | 9/30/2026 | View on chart |
| NC | ▲ Buy | Grant | 569 | — | 7/1/2026 | View on chart |
| LDOS | ▲ Buy | Grant | 7 | $0 | 6/30/2026 | View on chart |
| LDOS | ▲ Buy | Grant | 1,067 | $0 | 5/8/2026 | View on chart |
| NC | ▲ Buy | Grant | 563 | — | 4/1/2026 | View on chart |
| LDOS | ▲ Buy | Grant | 5 | $0 | 3/31/2026 | View on chart |
| LDOS | ▲ Buy | Option Exercise | 3,345 | $251K | 2/19/2026 | View on chart |
| LDOS | ▼ Sell | Tax Withholding | 1,463 | $251K | 2/19/2026 | View on chart |
| NC | ▲ Buy | Grant | 604 | — | 1/2/2026 | View on chart |
| LDOS | ▲ Buy | Grant | 4 | $0 | 12/31/2025 | View on chart |
| NC | ▲ Buy | Grant | 707 | — | 10/1/2025 | View on chart |
| LDOS | ▲ Buy | Grant | 3 | $0 | 9/30/2025 | View on chart |
| NC | ▲ Buy | Grant | 770 | — | 7/1/2025 | View on chart |
| LDOS | ▲ Buy | Grant | 4 | $0 | 6/30/2025 | View on chart |
| LDOS | ▲ Buy | Grant | 873 | $0 | 5/9/2025 | View on chart |
| NC | ▲ Buy | Grant | 868 | — | 4/1/2025 | View on chart |
| LDOS | ▲ Buy | Grant | 5 | $0 | 3/28/2025 | View on chart |
| LDOS | ▲ Buy | Option Exercise | 4,070 | $257K | 2/25/2025 | View on chart |
| LDOS | ▼ Sell | Tax Withholding | 2,002 | $257K | 2/25/2025 | View on chart |
| NC | ▲ Buy | Grant | 928 | — | 1/2/2025 | View on chart |
| LDOS | ▲ Buy | Grant | 4 | $0 | 12/31/2024 | View on chart |
| NC | ▲ Buy | Grant | 974 | — | 10/1/2024 | View on chart |
| LDOS | ▲ Buy | Grant | 4 | $0 | 9/27/2024 | View on chart |
| NC | ▲ Buy | Grant | 902 | — | 7/1/2024 | View on chart |
| LDOS | ▲ Buy | Grant | 4 | $0 | 6/28/2024 | View on chart |
| LDOS | ▲ Buy | Grant | 912 | $0 | 5/3/2024 | View on chart |
| LDOS | ▲ Buy | Option Exercise | 4,788 | $252K | 5/2/2024 | View on chart |
| LDOS | ▼ Sell | Tax Withholding | 1,775 | $252K | 5/2/2024 | View on chart |
| LDOS | ▲ Buy | Grant | 18 | $0 | 4/26/2024 | View on chart |
| NC | ▲ Buy | Grant | 814 | — | 4/1/2024 | View on chart |
| NC | ▲ Buy | Grant | 781 | — | 1/2/2024 | View on chart |
| NC | ▲ Buy | Grant | 810 | — | 10/2/2023 | View on chart |
| LDOS | ▲ Buy | Option Exercise | 5,193 | $206K | 8/4/2023 | View on chart |
| LDOS | ▼ Sell | Tax Withholding | 2,096 | $206K | 8/4/2023 | View on chart |
| NC | ▲ Buy | Grant | 806 | — | 7/5/2023 | View on chart |
| LDOS | ▲ Buy | Grant | 1,574 | $0 | 5/5/2023 | View on chart |
| LDOS | ▲ Buy | Open Market | 2,500 | $197K | 5/4/2023 | View on chart |
| LDOS | ▲ Buy | Open Market | 2,500 | $197K | 5/4/2023 | View on chart |
| NC | ▲ Buy | Grant | 732 | — | 4/3/2023 | View on chart |
| NC | ▲ Buy | Grant | 588 | — | 1/3/2023 | View on chart |
| NC | ▲ Buy | Grant | 635 | — | 10/3/2022 | View on chart |
| NC | ▲ Buy | Grant | 579 | — | 7/1/2022 | View on chart |
| LDOS | ▲ Buy | Grant | 1,106 | $0 | 5/6/2022 | View on chart |
| NC | ▲ Buy | Grant | 841 | — | 4/1/2022 | View on chart |
| LDOS | ▲ Buy | Option Exercise | 10,523 | $333K | 3/4/2022 | View on chart |
| LDOS | ▼ Sell | Tax Withholding | 3,167 | $333K | 3/4/2022 | View on chart |
| NC | ▲ Buy | Grant | 808 | — | 1/3/2022 | View on chart |
| NC | ▲ Buy | Grant | 1,014 | — | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Leidos wins new defense and health contracts
Leidos Holdings recently secured new contracts for logistics support in the UK and health research for the U.S. Navy. These wins highlight the company's ongoing role in defense and health services. The stock is currently trading well below the average analyst target price, suggesting potential value for some investors.
Leidos wins new defense and health contracts. Leidos Holdings recently secured new contracts for logistics support in the UK and health research for the U.S. Navy. These wins highlight the company's ongoing role in defense and health services. The stock is currently trading well below the average analyst target price, suggesting potential value for some investors.